Notably, these molecular defects were retained in RCC patient TC even after extended rounds of MLTC stimulation, suggesting the need for sustained, targeted intervention if complete “normalization” of the RCC patient anti-tumor CD8+ T effector cell repertoire is desired as a (clinical) endpoint. Here, CD8A is linked to renal cell carcinoma.